{ "items": [ "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Buddha\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Buddha Basnyat joins the RSTMH Board of Trustees\n

\n\n\n\n

\n \n 14 May 2021\n \n

\n\n \n

\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Nepal\n \n \n\n \n\n\n

\n \n\n \n \n \n

Director for the Oxford University Clinical Research Unit Nepal, Professor Buddha Basnyat is a medical doctor based in Kathmandu, Nepal. His research interests are infectious diseases and high altitude medicine, and he has almost 300 publications in peer-reviewed medical journals. One of his primary interests is to encourage young people to do clinical research.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Arjen\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Arjen Dondorp, Peter Horby and Rose McGready elected Academy of Medical Sciences Fellows\n

\n\n\n\n

\n \n 12 May 2021\n \n

\n\n \n

\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n MORU\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

\"Although it is hard to look beyond the pandemic right now,\" says President of the Academy of Medical Sciences Professor Dame Anne Johnson, \"I want to stress how important it is that the Academy Fellowship represents the widest diversity of biomedical and health sciences. The greatest health advances rely on the findings of many types of research, and on multidisciplinary teams and cross-sector and global collaboration.\"

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Banner\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Pint of Science Thailand is back, now online\n

\n\n\n\n

\n \n 7 May 2021\n \n

\n\n \n

\n \n\n \n \n \n \n MORU\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n

\n \n\n \n \n \n

Live and on-line from Bangkok! Be ready for Thursday 13th May, when Pint of Science Thailand will stream live from Bangkok. Join us via Facebook, YouTube or right here from the Pint of Science Thailand website as we journey from bacterial infections to viruses, discover how clinical trials work, and how scientific development is seen in the eyes of the law!

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Maps\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n We gathered rich insights into child survival in Kenya by mapping patterns over 22 years\n

\n\n\n\n

\n \n 5 May 2021\n \n

\n\n \n

\n \n\n \n \n \n \n KWTRP\n \n \n\n \n\n\n

\n \n\n \n \n \n

Although improvements in child survival globally have been remarkable, 5.2 million children still died in 2019, over half of these in sub-Saharan Africa. A range of factors likely include disparities in childhood immunisations, supplements and breastfeeding practices, antenatal care, skilled birth attendants working in healthcare facilities. Kenya needs to prioritise its child care plans, based on localities and populations with the greatest need. Two KWTRP studies give granular insights into the situation in regions across Kenya.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Mourners\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n How Nepal can survive a second COVID wave\n

\n\n\n\n

\n \n 5 May 2021\n \n

\n\n \n

\n \n\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Nepal\n \n \n\n \n\n\n

\n \n\n \n \n \n

Nepal is seeing a COVID surge that is proportionately similar to India. While we try to treat the sick by increasing hospital space and ensuring oxygen supply, we must also plan for an exit strategy. Over-preparation rather than under-preparedness needs to be our mantra, with widespread vaccination the key to get us out of this pandemic, by Professor Buddha Basnyat

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Francis\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n What it takes to reach zero malaria\n

\n\n\n\n

\n \n 4 May 2021\n \n

\n\n \n

\n \n\n \n \n \n \n KWTRP\n \n \n\n \n\n\n

\n \n\n \n \n \n

Interview with KWTRP Malaria immunologist Dr Francis Ndungu. Francis grew up in central Kenya where malaria is not prevalent but is interested in understanding of how semi-immune individuals control malaria parasite growth and the associated inflammation symptoms. His current work is in understanding how we develop immunity to Malaria. He is also interested in the potential translation of that knowledge in the development of effective malaria vaccines.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Image\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Celebrating women in ICT: connected girls, creating brighter futures\n

\n\n\n\n

\n \n 27 April 2021\n \n

\n\n \n

\n \n\n \n \n \n \n KWTRP\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n

\n \n\n \n \n \n

The International Girl\u2019s in ICT day is commemorated to create awareness on the critical need for more girls and women in the ICT sector, encourage and inspire young girls to actively pursue careers in STEM as well as engage the community to promote collaboration through partnerships. Kathreen Wafula, an ICT Support Technician in Kilifi, joins a strong team of techies and is one of the 4 women in the department.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Photo\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Communicating with communities for World Immunisation Week 2021\n

\n\n\n\n

\n \n 26 April 2021\n \n

\n\n \n

\n \n\n \n \n \n \n OUCRU\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n

\n \n\n \n \n \n

World Immunization Week highlights the role vaccinations play in improving the health of communities. As the COVID pandemic continues to impact countries worldwide, governments are facing challenges related to coverage, equity and sustainability of routine immunisation alongside access and the particular maintenance requirements related to the SARS-CoV-2 vaccines. Communication with communities has been key to ensure continued engagement with the vaccine programs despite the challenges of current contexts.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Children\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Innovative strategies for engaging communities with malaria research\n

\n\n\n\n

\n \n 25 April 2021\n \n

\n\n \n

\n \n\n \n \n \n \n MORU\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n

\n \n\n \n \n \n

For World Malaria Day 2021, F1000 Research Blog spoke to Professor Phaik Yeong Cheah about her research focussed on drama and arts-based community engagement for malaria research, published with Wellcome Open Research.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Two\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n New project\u2019s child-appropriate primaquine doses could have significant impact on global burden of malaria\n

\n\n\n\n

\n \n 23 April 2021\n \n

\n\n \n

\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n

\n \n\n \n \n \n

On Sunday 25 April, World Malaria Day, the Developing Paediatric Primaquine (DPP) project will launch its website. DPP will produce children-appropriate primaquine doses that could both cut malaria deaths in vulnerable African children by blocking transmission of P. falciparum malaria and reduce P. vivax malaria more widely.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Two\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Supporting children to grow smarter, not just taller\n

\n\n\n\n

\n \n 21 April 2021\n \n

\n\n \n

\n \n\n \n \n \n \n EOCRU\n \n \n \n \n OUCRU\n \n \n\n \n\n\n

\n \n\n \n \n \n

Anuraj Shankar from our EOCRU unit in Jakarta, Indonesia, with Elizabeth Prado and Leila Larson describe a meta-analysis showing that responsive caregiving boosts infants\u2019 brain development. Parenting group sessions and home visits improve cognitive, language, and motor skills. And nutrition-only programmes have much less effect than comprehensive interventions.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Female\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Risks of serious adverse events following treatment for visceral leishmaniasis\n

\n\n\n\n

\n \n 30 March 2021\n \n

\n\n \n

\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Child's\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n World TB Day: Finding new ways to test children for tuberculosis\n

\n\n\n\n

\n \n 24 March 2021\n \n

\n\n \n

\n \n\n \n \n \n \n General\n \n \n\n \n\n\n

\n \n\n \n \n \n

Every year, over a million children fall ill with tuberculosis (TB) globally, and about a quarter die from this potentially preventable and curable disease. The main challenge remains the diagnosis of TB, especially in resource-constrained settings. We currently need to collect mucus from the lungs or liquid contents of the stomach, which must be collected in a hospital. Different ways to diagnosis TB in children are urgently needed, especially for those infected with HIV. An international collaboration is now conducting a large diagnostic study in Uganda to fill this gap. The study aims to detect TB bacteria in body fluids such as blood, urine, stool and saliva that are easier to collect.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"pills\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n The RECOVERY Trial: One year on\n

\n\n\n\n

\n \n 23 March 2021\n \n

\n\n \n

\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"African\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Researchers call for access to Ivermectin for young children\n

\n\n\n\n

\n \n 19 March 2021\n \n

\n\n \n

\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network\u2019s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Three\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Gender imbalance in visceral leishmaniasis clinical trials\n

\n\n\n\n

\n \n 17 March 2021\n \n

\n\n \n

\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Gloved\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n New report highlights growing concern of vaccine falsification\n

\n\n\n\n

\n \n 16 March 2021\n \n

\n\n \n

\n \n\n \n \n \n \n MORU\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Colchicine\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19\n

\n\n\n\n

\n \n 5 March 2021\n \n

\n\n \n

\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms \u2013 aspirin, baricitinib, Regeneron\u2019s antibody cocktail, and dimethyl fumarate \u2013 continues as planned.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Nepalese\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n World\u2019s largest clinical trial for COVID-19 treatments expands internationally\n

\n\n\n\n

\n \n 22 February 2021\n \n

\n\n \n

\n \n\n \n \n \n \n EOCRU\n \n \n \n \n OCGHR\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Nepal\n \n \n\n \n\n\n

\n \n\n \n \n \n

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world\u2019s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Vial\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Tocilizumab reduces deaths in patients hospitalised with COVID-19\n

\n\n\n\n

\n \n 12 February 2021\n \n

\n\n \n

\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that tocilizumab, an anti-inflammatory treatment, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Healthcare\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission\n

\n\n\n\n

\n \n 12 February 2021\n \n

\n\n \n

\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Geneva\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Geneva Health Forum panel on the elimination of NTDs and the new WHO Roadmap\n

\n\n\n\n

\n \n 5 February 2021\n \n

\n\n \n

\n \n\n \n \n \n \n Conferences & meetings\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

The WHO 2030 NTD Roadmap has just been launched, and a recent Geneva Health Forum panel took that as its starting point to discuss the possibility of eliminating neglected tropical diseases (NTDs). Professor Philippe Gu\u00e9rin, IDDO\u2019s Director, joined co-panellists Dr Amy Fall, the Global Health Medical for Africa Region Lead at Sanofi, Dr Mwele Malecela, Director of the Department of Control of Neglected Tropical Diseases at the WHO, and Dr Nathalie Strub-Wourgaft, Medical Director at Drugs for Neglected Diseases initiative (DNDi) back in November 2020.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Chemical\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Baricitinib to be investigated as a possible treatment for COVID-19 in the RECOVERY trial\n

\n\n\n\n

\n \n 3 February 2021\n \n

\n\n \n

\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

Baricitinib \u2013 an anti-inflammatory treatment for rheumatoid arthritis\u2013 is being investigated in the RECOVERY trial, the world\u2019s largest clinical trial of treatments for patients hospitalised with COVID-19, taking place in 177 hospital sites across the UK and with over 33,000 patients recruited so far. As an anti-inflammatory, baricitinib may block the signalling activity of cytokine molecules which contribute to the hyper-inflammatory state seen in severe COVID-19. It is thought that baricitinib may act also have some anti-viral activity. The other treatments currently being investigated in the RECOVERY trial are Regeneron\u2019s antibody cocktail, Aspirin and Colchicine.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"The\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Indonesia\u2019s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable\n

\n\n\n\n

\n \n 2 February 2021\n \n

\n\n \n

\n \n\n \n \n \n \n EOCRU\n \n \n \n \n MORU\n \n \n \n \n OUCRU\n \n \n\n \n\n\n

\n \n\n \n \n \n

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine\u2019s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Researchers\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Community and Public Engagement at KWTRP\n

\n\n\n\n

\n \n 28 January 2021\n \n

\n\n \n

\n \n\n \n \n \n \n KWTRP\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n

\n \n\n \n \n \n

KWTRP initial community and public engagement strategy was developed in 2005 with three goals: build understanding and trust between researchers and communities, enhance ethical conduct of research, and disseminate research findings to promote uptake into policy. Our programme has since developed and now includes engagement with media, radio programme, media engagement workshops, various meetings and forums, and a fully-fledged school engagement programme that was awarded the 2019 Oxford VC Public Engagement with Research Award.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Volunteer\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19\n

\n\n\n\n

\n \n 15 January 2021\n \n

\n\n \n

\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms \u2013 tocilizumab, aspirin, colchicine, and Regeneron\u2019s antibody cocktail \u2013 continues as planned.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Two\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Check-list recommended to improve reporting of microscopy methods and results in malaria studies\n

\n\n\n\n

\n \n 13 January 2021\n \n

\n\n \n

\n \n\n \n \n \n \n MORU\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Two\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n UK National Health Service begins rollout of Oxford coronavirus vaccine\n

\n\n\n\n

\n \n 5 January 2021\n \n

\n\n \n

\n \n\n \n \n \n \n General\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

The first patients are being vaccinated as part of the UK\u2019s rollout of the Oxford / AstraZeneca coronavirus vaccine, ChAdOx1 nCoV-19, at the Oxford University NHS Hospitals Trust. The Oxford AstraZeneca vaccinations will be delivered at a small number of hospitals for the first few days for surveillance purposes, as is standard practice, before the bulk of supplies are sent to hundreds of GP-led services later in the week.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Photograph\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Pearl Gan, OUCRU Photographer in Residence, selected for the Lancet Highlights 2020\n

\n\n\n\n

\n \n 4 January 2021\n \n

\n\n \n

\n \n\n \n \n \n \n OUCRU\n \n \n\n \n\n\n

\n \n\n \n \n \n

Congratulations to Pearl Gan, OUCRU Photographer in Residence, for her winning image selected for the Lancet Highlights 2020: Framing Health Stories. Despite the difficulties of this pandemic year, The Lancet received fascinating and varied entries for our Highlights 2020 photography competition. 15 striking photographs were selected. Each picture captures a unique moment, highlighting a health story.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"A\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Receiving and responding to community feedback during health system crises in Kenya\n

\n\n\n\n

\n \n 18 December 2020\n \n

\n\n \n

\n \n\n \n \n \n \n KWTRP\n \n \n\n \n\n\n

\n \n\n \n \n \n

The responsiveness of a health system is one of its goals, alongside fairness in financing and outcomes. Listening and responding to the public can make a health system stronger and fairer. However, responsiveness is likely to be undermined, especially for vulnerable and marginal populations, in periods of crises such as disease outbreaks. In the current COVID-19 crisis, there has been more focus on health system control interventions, with minimal consideration of community views. KWTRP colleagues in Kenya consider community engagement and citizens feedback channels, concerns raised by the public and how they were handled, and highlight lessons learned.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Professor\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Susie Dunachie awarded flagship NIHR career development award\n

\n\n\n\n

\n \n 16 December 2020\n \n

\n\n \n

\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Coronavirus\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19\n

\n\n\n\n

\n \n 15 December 2020\n \n

\n\n \n

\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

Established in March 2020, the RECOVERY trial tests a range of potential treatments for COVID-19, including azithromycin, a widely used antibiotic that also reduces inflammation. The azithromycin arm of the trial was established to determine whether or not the drug has a meaningful benefit among patients hospitalised with COVID-19. A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality; there was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Photo\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n AfOx receives the Wellcome Institutional Strategic Support Fund to launch the Africa Health Innovation Platform\n

\n\n\n\n

\n \n 11 December 2020\n \n

\n\n \n

\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

AfOx in collaboration with partners across the UK and Africa has received a Wellcome Institutional Strategic Support Fund to establish an Africa Health Innovation Platform. The multi-disciplinary platform will support African innovators who develop new solutions to Africa\u2019s health challenges, bringing together researchers, entrepreneurs, investors, technologists, policymakers, and change leaders to develop new approaches towards prevention, early detection and treatment of diseases.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"AHOP\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Knowledge brokering platform launched to support health systems in the African region\n

\n\n\n\n

\n \n 8 December 2020\n \n

\n\n \n

\n \n\n \n \n \n \n KWTRP\n \n \n\n \n\n\n

\n \n\n \n \n \n

The World Health Organization and partners including the KEMRI Wellcome Trust Research Programme launched AHOP (African Health Observatory Platform), an online platform to promote the exchange of evidence and experience across countries in the African region. By working to foster evidence-informed decision-making in an endeavor to re-engineer health service delivery, the initiative is expected to drive countries\u2019 health system resilience efforts.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Coronavirus\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n The COVID-19 vaccine: do we know enough to end the pandemic?\n

\n\n\n\n

\n \n 7 December 2020\n \n

\n\n \n

\n \n\n \n \n \n \n MORU\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Poster\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Restoring confidence in science \u2013 tinkering in the margin is not enough\n

\n\n\n\n

\n \n 4 December 2020\n \n

\n\n \n

\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

Blog by Piero Olliaro, Josephine Bourner and Lakshmi Manoharan. The COVID-19 pandemic has highlighted the limits of the current peer-review model, which is collapsing under the number of articles and volume of information, unable to cope with the conflicting needs for speed and quality of information. The peer review process is often slow, opaque, unaccountable and biased; it is now time to focus on tangible improvements, making transparency our top priority. We need a system reset, not tinkering in the margin.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Mother\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria\n

\n\n\n\n

\n \n 1 December 2020\n \n

\n\n \n

\n \n\n \n \n \n \n MORU\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Claire\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Clare Ling awarded honorary FRCPath\n

\n\n\n\n

\n \n 23 November 2020\n \n

\n\n \n

\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n MORU\n \n \n \n \n SMRU\n \n \n\n \n\n\n

\n \n\n \n \n \n

Dr Clare Ling has been made an honorary Fellow of the Royal College of Pathologists (FRCPath). Currently running Shoklo Malaria Research Unit (SMRU) Microbiology department and supporting the unit\u2019s molecular activities, Clare is a clinical scientist who has worked at SMRU on the Thai-Myanmar border since 2012.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Numerous\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Youth against antimicrobial resistance\n

\n\n\n\n

\n \n 23 November 2020\n \n

\n\n \n

\n \n\n \n \n \n \n OUCRU\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n

\n \n\n \n \n \n

The YAAR! project, bringing together young people from four countries in the Global South to help combat the challenge of antimicrobial resistance (AMR), or drug resistant infections.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Pakistan\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Aga Khan University enrols first COPCOV Pakistan participant\n

\n\n\n\n

\n \n 18 November 2020\n \n

\n\n \n

\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n

\n \n\n \n \n \n

As the world anxiously awaits COVID-19 vaccines, people working in healthcare settings remain at risk of infection from COVID-19. The Pakistani arm of COPCOV, the global study to test if hydroxychloroquine or chloroquine can prevent COVID-19 in healthcare workers, has begun to enrol participants at Aga Khan University, joining sites in the UK and Thailand.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Ed\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Aiming for more effective remote communication between Oxford and the AAPs\n

\n\n\n\n

\n \n 11 November 2020\n \n

\n\n \n

\n \n\n \n \n \n \n MORU\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

In an effort to foster closer interactions and collaboration, CTMGH learned long ago to make the best of the plethora of communication tools available. In this era of video conferences, we are all familiar with the limitations of various 2D options. Could new technologies help us devise better communication to enhance collaboration and teaching opportunities? In an effort to find new solutions, a group of NDM staff visited London and interacted as a hologram with colleagues in Bangkok.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"FIEBRE\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n FIEBRE Laos concludes recruitment\n

\n\n\n\n

\n \n 9 November 2020\n \n

\n\n \n

\n \n\n \n \n \n \n LOMWRU\n \n \n \n \n MORU\n \n \n\n \n\n\n

\n \n\n \n \n \n

Congratulations to everyone involved in contributing to FIEBRE\u2019s success - the clinical and laboratory staff, hospital, participants and local communities. The team has continued working throughout the COVID-19 epidemic despite national restrictions which slowed down enrolment and limited field activities.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Aspirin\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Aspirin to be investigated as a possible treatment for COVID-19 in the RECOVERY trial\n

\n\n\n\n

\n \n 6 November 2020\n \n

\n\n \n

\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

Aspirin will be investigated in the world\u2019s largest clinical trial of treatments for patients hospitalised with COVID-19. The RECOVERY trial is taking place in 176 hospital sites across the UK, and has so far recruited over 16,000 patients. Patients with COVID-19 are at higher risk of blood clots forming in their blood vessels. Platelets seem to be hyperreactive in COVID-19 and may be involved in the clotting complications. As an antiplatelet agent, aspirin may reduce the risk of blood clots in patients with COVID-19.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Headshots\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Applicability of COVID-19 vaccine trial results to low-and-middle-income countries\n

\n\n\n\n

\n \n 5 November 2020\n \n

\n\n \n

\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n

\n \n\n \n \n \n

In the next few months, the first Phase 3 COVID-19 vaccine trials \u2013 the majority of them in upper-middle or high-income countries and in specific target populations like young adults \u2013 will report their results. How relevant will their study results be for low-resource settings?

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Kenyan\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Trials of Oxford coronavirus vaccine begin in Kenya\n

\n\n\n\n

\n \n 30 October 2020\n \n

\n\n \n

\n \n\n \n \n \n \n KWTRP\n \n \n\n \n\n\n

\n \n\n \n \n \n

Kenya has joined the global efforts in search of an effective vaccine for COVID-19 with the start of a trial evaluating the ChAdOx1 nCoV-2019 Oxford coronavirus vaccine. Following the necessary approvals from regulators, as well as the national ministry of health, and Kilifi county, the first volunteers for the trial have recently received their vaccinations.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Photographer\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Life at the Thai-Myanmar border through the eyes of a frontline researcher\n

\n\n\n\n

\n \n 30 October 2020\n \n

\n\n \n

\n \n\n \n \n \n \n MORU\n \n \n \n \n Public Engagement\n \n \n \n \n SMRU\n \n \n\n \n\n\n

\n \n\n \n \n \n

Ethox programme REACH (Resilience, Empowerment and Advocacy in Women's and Children's Health Research) posted a visual research gallery as a Public Engagement project. Six galleries of photos by SMRU's Suphak Nosten depict aspects of migrant workers' daily lives: the Thai-Myanmar border; work; cultural and spiritual values; the often-difficult journeys seeking healthcare; striving for better; and dedicated frontline health workers. Richly coloured, sometimes personal, Suphak\u2019s photography is deeply empathetic and memorable.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Liz\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Congratulations new NDM professors\n

\n\n\n\n

\n \n 30 October 2020\n \n

\n\n \n

\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n LOMWRU\n \n \n \n \n MORU\n \n \n\n \n\n\n

\n \n\n \n \n \n

The University of Oxford has awarded CTMGH two new Professors. Elisabeth Ashley - UK-trained physician who specialises in infectious diseases and medical microbiology & virology, and Director of the Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU) in Lao PDR since 2019, Liz is conferred the title of Professor of Tropical Medicine. Stuart Blacksell - Senior Research Scientist based at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) in Thailand, Stuart is conferred the title of Professor of Tropical Microbiology.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Profesor\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n British Pharmacology Society honours Joel Tarning\n

\n\n\n\n

\n \n 28 October 2020\n \n

\n\n \n

\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n MORU\n \n \n\n \n\n\n

\n \n\n \n \n \n

We are pleased to announce that Prof Joel Tarning has been awarded the biennial Grahame-Smith Prize by the British Pharmacological Society for outstanding contributions to clinical pharmacology. Joel has headed MORU's Clinical Pharmacology Department since 2012. Since then, the Department has grown into large, productive group that conducts laboratory- and computer-based pharmacology research.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"ISARIC\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n IDDO and ISARIC partner to support data collection and analysis for COVID-19\n

\n\n\n\n

\n \n 27 October 2020\n \n

\n\n \n

\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n

\n \n\n \n \n \n

In January 2020, ISARIC launched an international initiative for standardised COVID-19 clinical data collection. To date, ISARIC has collected data from over 118,000 individuals from 648 sites across 52 countries. To maximise the impact of this global collaboration, ISARIC has partnered with IDDO, which has over a decade\u2019s worth of experience in collecting and standardising disparate data from various diseases and areas around the world. Together, ISARIC and IDDO are developing systems that include working with those who collect the data to generate collaborative analysis, and building data governance systems that allow data to be shared more widely.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Map\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Oxford Global Research\n

\n\n\n\n

\n \n 23 October 2020\n \n

\n\n \n

\n \n\n \n \n \n \n General\n \n \n \n \n KWTRP\n \n \n \n \n MORU\n \n \n \n \n OCGHR\n \n \n \n \n OUCRU\n \n \n\n \n\n\n

\n \n\n \n \n \n

Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. To showcase our global research, the University launched a Global Research Map, highlighting areas of research we are conducting overseas.

\n \n\n
\n\n
\n\n
\n\n\n" ], "more": "\n\n \n \n Load More\n \n \n\n", "msg": "" }